B
BioLineRx Ltd. (BLRX)
NCM – Real Time Price. Currency in USD
2.81
+0.03 (1.08%)
At close: Aug 12, 2026, 1:26 PM EDT
2.58
-0.11 (-4.09%)
After-hours: Aug 12, 2026, 5:51 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.81
+0.03 (1.08%)
At close: Aug 12, 2026, 1:26 PM EDT
2.58
-0.11 (-4.09%)
After-hours: Aug 12, 2026, 5:51 PM EDT
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
| Name | Position |
|---|---|
| Dr. Ella Sorani Ph.D. | Chief Development Officer |
| Mr. John Lacey | Head of Corporate Communications & Investor Relations |
| Mr. Philip A. Serlin CPA, M.B.A. | Chief Executive Officer |
| Mr. Raziel Fried | Treasurer & Budgetary Control Director |
| Ms. Mali Zeevi CPA | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-07-08 | 6-K | zk2635661.htm |
| 2026-05-27 | 6-K | zk2635421.htm |
| 2026-05-22 | 6-K | zk2635386.htm |
| 2026-05-19 | 6-K | zk2635368.htm |
| 2026-04-28 | 6-K | zk2635143.htm |
| 2026-03-27 | 20-F/A | zk2634966.htm |
| 2026-03-26 | 6-K | zk2634945.htm |
| 2026-03-23 | 6-K | zk2634888.htm |
| 2026-03-23 | 20-F | zk2634707.htm |
| 2026-02-23 | 6-K | zk2634422.htm |